Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
273 ^USD	-0.23%		+3.39%	-5.21%

Apr. 22	Wall Street: tech and SOXX in free fall this week	CF
Apr. 19	Wall Street: tech and SOXX in free fall this week	CF

AMGEN INC : Goldman Sachs maintains a Buy rating

April 28, 2021 at 07:30 am EDT

In his latest research note, analyst Terence Flynn confirms his positive recommendation. The broker Goldman Sachs is keeping its Buy rating. The target price has been raised from USD 281 to USD 290.

Latest news about Amgen Inc.

Wall Street: tech and SOXX in free fall this week	Apr. 22	CF
Wall Street: tech and SOXX in free fall this week	Apr. 19	CF
UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating	Apr. 17	MT
Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease	Apr. 16	MT
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept	Apr. 15	MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating	Apr. 15	MT
Neumora's early-stage schizophrenia drug study put on hold	Apr. 15	RE
BMO Lowers Price Target on Amgen to $336 From $343	Apr. 12	MT
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen	Apr. 09	MT
Morgan Stanley Cuts Price Target on Amgen to $271 From $278, Keeps Equalweight Rating	Apr. 09	MT
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Amgen Presents New Research on Otezla at AAD 2024	Mar. 09	CI
Amgen Keeps Q2 Dividend at $2.25 a Share, Payable June 7 to Stockholders of Record May 17	Mar. 06	MT
Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024	Mar. 06	CI
Transcript : Amgen Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM	Mar. 05
Wall Street: horizontal consolidation	Feb. 28	CF
Stocks take a breather as key inflation data eyed	Feb. 27	RE
WallStreet: consolidates horizontally, US stats more mixed	Feb. 27	CF
Stocks stall as key inflation data awaited	Feb. 27	RE
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
US STOCK-Wall Street wavers ahead of key inflation data	Feb. 27	RE
Amgen Opens Manufacturing Site in Central Ohio	Feb. 26	MT
Amgen Inc. Announces the Opening of Manufacturing Site in Central Ohio	Feb. 26	CI

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

273 USD

Average target price

300.3 USD

Spread / Average Target

+9.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	-5.21%	146B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+22.93%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+13.06%	219B
ROCHE HOLDING AG	-9.57%	196B
NOVARTIS AG	+6.37%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

AMGEN INC : Goldman Sachs maintains a Buy rating

Latest news about Amgen Inc.

Chart Amgen Inc.

Company Profile

Income Statement Evolution

Ratings for Amgen Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals